Amniotics AB granted key U.S. patent for PulmoStem™ – Positive news!

Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

There are currently no effective therapies that prevent or cure ARDS. There is also no drug with adequate effect against ARDS triggered by COVID-19. Acute respiratory distress syndrome, ARDS, is characterized by an acute inflammatory condition with respiratory failure (lung dysfunction) and bilateral pulmonary edema associated with hypoxia.

Amniotics announced yesterday that the US Patent and Trademark Office (USPTO) has approved a patent application for the company’s stem cell product PulmoStem™. This newly allowed U.S. patent provides Amniotics with exclusive commercial rights in the U.S. at least until 2040 for the use of the amniotic derived stem cell product PulmoStem™ in the treatment of Acute Respiratory Distress Syndrome (ARDS).

“This is the first U.S. patent granted in Amniotics patent portfolio and it confirms that our stem cell products and production methods are patentable, novel, and innovative. This approval also validates our long-term IP strategy, matching high quality patent applications with Amniotics products, ensuring market exclusivity for Amniotics technology. This is a great milestone, reached via a team effort, and I want to take the opportunity to thank our founders, inventors, and external consultants including our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens”, says Kåre Engkilde, CEO at Amniotics. 

Disclaimer: HC Andersen Capital receives payment from Amniotics for a Digital IR / Corporate Visibility agreement